Results 181 to 190 of about 17,163 (245)

From Ototoxicity to Otoprotection: Mechanism and Protective Strategies in Cisplatin Therapy. [PDF]

open access: yesPharmaceuticals (Basel)
Iațentiuc A   +11 more
europepmc   +1 more source

Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis. [PDF]

open access: yesFront Oncol
de Jager KE   +5 more
europepmc   +1 more source

Delayed Complete Spontaneous Hearing Recovery in a Pediatric Chemotherapy Patient-A Case Report. [PDF]

open access: yesOTO Open
Bentan MA   +3 more
europepmc   +1 more source

Comparative Study of the Quality of Life of Patients With Ototoxicity Due to Platinum-Based Chemotherapy, With Hearing Aid Versus Those Without: Study Protocol for a Randomized Pilot Study-The PROTOTOX Study. [PDF]

open access: yesJMIR Res Protoc
Mastronicola R   +3 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Ototoxicity and Teprotumumab

Annals of Otology, Rhinology & Laryngology, 2021
Objectives: Teprotumumab, a novel monoclonal antibody, targets the insulin-like growth factor 1 (IGF-1) receptor. IGF-1 receptors, found in muscle and fat adjacent to the eye and implicated in Graves Ophthalmopathy, are also in the cochlea.
Julie Highland   +3 more
openaire   +2 more sources

Carboplatin is ototoxic

Cancer Chemotherapy and Pharmacology, 1990
For assessment of the ototoxic potential of carboplatin [cis-diammine-1,1-cyclobutane dicarboxylate platinum(II); CBDCA], pure-tone audiograms were evaluated in 27 patients receiving a total of 119 doses of carboplatin in the range of 300-400 mg/m2.
I C, Kennedy   +3 more
openaire   +2 more sources
cisplatin
hearing loss
cancer
ototoxicity monitoring
apoptosis
medicine
south africa
mitophagy
aminoglycosides
previous   17  18  19  20  21  

Home - About - Disclaimer - Privacy